<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775189</url>
  </required_header>
  <id_info>
    <org_study_id>B4531009</org_study_id>
    <nct_id>NCT01775189</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Single-dose, 4-way Crossover Study To Determine The Relative Abuse Potential Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended Release Capsules) Compared To Oxycodone Immediate Release, And Placebo When Administered Intranasally To Non-dependent, Recreational Opioid Users.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if oxycodone and naltrexone combination
      capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abuse Liability Study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Liking: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the extreme left with &quot;strong disliking&quot; (score of 0 mm) and on the extreme right with &quot;strong liking&quot; (score of 100 mm). Peak Effect (Emax) = Maximum observed score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hour</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the extreme left with &quot;strong disliking&quot; (score of 0 mm) and on the extreme right with &quot;strong liking&quot; (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-2 Hour</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
    <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
    <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = &quot;definitely would not&quot;, 50 mm = &quot;do not care&quot;, and 100 mm = &quot;definitely would&quot;). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again: Mean Effect (Emean)</measure>
    <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
    <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = &quot;definitely would not&quot;, 50 mm = &quot;do not care&quot;, and 100 mm = &quot;definitely would&quot;). Emean = Average observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again Effect at Hours 12 and 24</measure>
    <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
    <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = &quot;definitely would not&quot;, 50 mm = &quot;do not care&quot;, and 100 mm = &quot;definitely would&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
    <description>Overall drug liking VAS assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = &quot;strong disliking&quot;, 50 mm = &quot;neither like nor dislike&quot;, and 100 mm= &quot;strong liking&quot;). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking: Mean Effect (Emean)</measure>
    <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
    <description>Overall drug liking VAS assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = &quot;strong disliking&quot;, 50 mm = &quot;neither like nor dislike&quot;, and 100 mm= &quot;strong liking&quot;). Emean = Average observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking Effect at Hours 12 and 24</measure>
    <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
    <description>Overall drug liking VAS assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = &quot;strong disliking&quot;, 50 mm = &quot;neither like nor dislike&quot;, and 100 mm= &quot;strong liking&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Peak Effect (Emax)</measure>
    <time_frame>Intervention periods: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Dose (Drug Powder) Insufflated</measure>
    <time_frame>Intervention period: 0 Hour post-dose</time_frame>
    <description>The percentage of dose insufflated, was based on a calculation of the weight of powder remaining (if any) following each dosing during the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. Emax = Maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hour</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the left with &quot;strong disliking&quot; (score of 0 mm) and on the right with &quot;strong liking&quot; (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug Liking: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the left with &quot;strong disliking&quot; (score of 0 mm) and on the right with &quot;strong liking&quot; (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </other_outcome>
  <other_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hours</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
  </other_outcome>
  <other_outcome>
    <measure>High: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject Rating Scale for Nasal Effects: Peak Effect (Emax)</measure>
    <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
    <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem &quot;as bad as can be&quot;). Emax = Maximum observed score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-1 Hour and 0-2 Hour</measure>
    <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
    <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem &quot;as bad as can be&quot;). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject Rating Scale for Nasal Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
    <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem &quot;as bad as can be&quot;). TEmax = Time to maximum observed score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Oxycodone, Oxymorphone and Noroxycodone</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Naltrexone and 6-beta-naltrexol</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxycodone, Oxymorphone and Noroxycodone</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone and 6-beta-naltrexol</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Oxycodone, Oxymorphone and Noroxycodone</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Naltrexone and 6-beta-naltrexol</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Oxycodone, Oxymorphone and Noroxycodone</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 hours post-dose</time_frame>
    <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Oxycodone, Oxymorphone and Noroxycodone</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last quantifiable concentration (AUClast). Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Oxycodone, Oxymorphone and Noroxycodone</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Naltrexone and 6-beta-naltrexol</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 hours post-dose</time_frame>
    <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Naltrexone and 6-beta-naltrexol</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last quantifiable concentration (AUClast). Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone and 6-beta-naltrexol</measure>
    <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Screening up to 3 to 7 days following last study drug administration, or time of early withdrawal</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 3 - 7 days following last study drug administration that were absent before treatment or that worsened relative to pre-treatment state. Symptoms of withdrawal following naloxone administration (naloxone challenge phase) were not collected as adverse events unless they met the criteria for an SAE. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Sign Examinations</measure>
    <time_frame>Screening up to 3 to 7 days following last study drug administration, or time of early withdrawal</time_frame>
    <description>Vital signs assessment included measurement of heart rate, systolic and diastolic blood pressures, and respiratory rate. Criteria for clinically significant change in any vital sign examination was based on investigator's discretion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Clinically Significant Change in End Tidal Carbon Dioxide (EtCO2)</measure>
    <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>End-tidal carbon dioxide concentration in the expired air (EtCO2) was monitored using capnography in a sitting position. Criteria for clinically significant change in EtCO2 was based on investigator's discretion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Clinically Significant Change in Oxygen Saturation of Hemoglobin (SpO2)</measure>
    <time_frame>Drug discrimination phase: pre-dose up to 5 hours; intervention period: pre-dose up to 12 hours</time_frame>
    <description>Oxygen saturation of hemoglobin in blood (SpO2) was monitored using pulse oximetry continuously for 5 hours following dosing in the drug discrimination phase and continuously for 12 hours following dosing in the treatment phase, or longer at the discretion of the investigator. Individual measurement was collected in a sitting position. If SpO2 fall below 90 percent (%), the investigator administered oxygen via nasal cannula at a flow rate sufficient to maintain the SpO2 greater than or equal to 90%. Participants with fall in SpO2 below 90% were reported.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALO-02 weight-matched placebo</intervention_name>
    <description>crushed sugar spheres (powder) x 1 dose</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crushed ALO-02 30 mg/3.6 mg</intervention_name>
    <description>crushed ALO-02 30 mg/3.6 mg capsule x 1 dose</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone weight-matched placebo</intervention_name>
    <description>crushed lactose tablets (powder) x 1 dose</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crushed oxycodone IR 30 mg</intervention_name>
    <description>Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Non-dependent, recreational opioid users. (Must use opioid for non-therapeutic
             purposes on at least 10 occassions within the last year and at least once in the 8
             weeks before Visit 1 (Screening Visit).

          -  Must have experience with intranasal opioid administration (snorted opioid drugs on at
             least 3 occassions within the last year before Visit 1 (Screening Visit).

        Exclusion Criteria:

          -  Diagnosis of substance and/or alcohol dependence

          -  Subject has participated in, is currently participating in, or seeking treatment for
             substance and/or alcohol related disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INC Research Toronto Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531009&amp;StudyName=A%20Study%20to%20Characterize%20the%20Abuse%20Liability%20of%20ALO-02%20in%20Healthy%2C%20Non-Dependent%2C%20Recreational%20Opioid%20Users%20When%20ALO-02%20Capsules%20are%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <results_first_submitted>October 6, 2016</results_first_submitted>
  <results_first_submitted_qc>April 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2017</results_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relative abuse potential study</keyword>
  <keyword>Chronic pain</keyword>
  <keyword>oxycodone</keyword>
  <keyword>naltrexone</keyword>
  <keyword>opioid-related disorders</keyword>
  <keyword>drug abusers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recreational opioid users who had experience with intranasal administration of opiates and were not dependent on opioids based on Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) criteria, were recruited in this study.</recruitment_details>
      <pre_assignment_details>After successful naloxone challenge test, all participants underwent training sessions involving complete pharmacodynamics test battery before the drug discrimination phase, to ensure that participants fully understood how to perform the tests, were comfortable, and attained a stable level of performance on the various performance-based measures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Naloxone</title>
          <description>Naloxone hydrochloride (HCl) 0.2 milligram (mg) intravenously followed by additional 0.6 mg naloxone hydrochloride intravenously on Day 0, each dose followed by an assessment for signs and symptoms of opioid withdrawal. Participants who did not display signs and symptoms of opioid withdrawal, were assigned to either oxycodone HCl 30 mg then placebo or placebo then oxycodone HCl 30 mg group in the drug discrimination phase of the study.</description>
        </group>
        <group group_id="P2">
          <title>Oxycodone HCl 30 mg Then Placebo</title>
          <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally on Day 1 followed by single dose of placebo matched to oxycodone HCl 30 mg crushed tablet intranasally on Day 2. Participants were assigned to receive oxycodone HCl 30 mg and naltrexone HCl 3.6 mg extended-release (ALO-02) 30 mg/3.6 mg crushed capsule, placebo matched to ALO-02 30 mg/3.6 mg crushed capsule (placebo sugar spheres, PBO SS), oxycodone 30 mg crushed tablet (OXY 30 mg), placebo matched to oxycodone 30 mg crushed tablet (placebo lactose tablet, PBO Lac), intranasally, in any of the 4 sequences in the treatment phase of the study.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Then Oxycodone HCl 30 mg</title>
          <description>Single dose of placebo matched to oxycodone HCl 30 mg crushed tablet intranasally on Day 1 followed by single dose of oxycodone HCl 30 mg crushed tablet intranasally on Day 2. Participants were assigned to receive ALO-02 30 mg/3.6 mg crushed capsule, placebo matched to ALO-02 30 mg/3.6 mg crushed capsule (PBO SS), oxycodone 30 mg crushed tablet (OXY 30 mg), placebo matched to oxycodone 30 mg crushed tablet (PBO Lac), intranasally, in any of the 4 sequences in the treatment phase of the study.</description>
        </group>
        <group group_id="P4">
          <title>PBO Lac, OXY 30 mg, ALO-02 30 mg, PBO SS</title>
          <description>Single dose of placebo matched to oxycodone (PBO Lac) 30 mg crushed tablet intranasally in first intervention period; followed by single dose of oxycodone HCl 30 mg (OXY 30 mg) crushed tablet intranasally in second intervention period; then single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in third intervention period; then single dose of placebo matched to ALO-02 (PBO SS) 30 mg/3.6 mg capsule intranasally in fourth intervention period. A washout period of at least 5 days (not exceeding 14 days) was maintained between each intervention period.</description>
        </group>
        <group group_id="P5">
          <title>ALO-02 30 mg, PBO Lac, PBO SS, OXY 30 mg</title>
          <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in first intervention period; followed by single dose of placebo matched to oxycodone (PBO Lac) 30 mg crushed tablet intranasally in second intervention period; then single dose of placebo matched to ALO-02 (PBO SS) 30 mg/3.6 mg crushed capsule intranasally in third intervention period; then single dose of oxycodone HCl 30 mg (OXY 30 mg) crushed tablet intranasally in fourth intervention period. A washout period of at least 5 days (not exceeding 14 days) was maintained between each intervention period.</description>
        </group>
        <group group_id="P6">
          <title>OXY 30 mg, PBO SS, PBO Lac, ALO-02 30 mg</title>
          <description>Single dose of oxycodone HCl 30 mg (OXY 30 mg) crushed tablet intranasally in first intervention period; followed by single dose of placebo matched to ALO-02 (PBO SS) 30 mg/3.6 mg crushed capsule intranasally in second intervention period; then single dose of placebo matched to oxycodone (PBO Lac) 30 mg crushed tablet intranasally in third intervention period; then single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in fourth intervention period. A washout period of at least 5 days (not exceeding 14 days) was maintained between each intervention period.</description>
        </group>
        <group group_id="P7">
          <title>PBO SS, ALO-02 30 mg, OXY 30 mg, PBO Lac</title>
          <description>Single dose of placebo matched to ALO-02 (PBO SS) 30 mg/3.6 mg crushed capsule intranasally in first intervention period; followed by single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in second intervention period; then single dose of oxycodone HCl 30 mg (OXY 30 mg) crushed tablet intranasally in third intervention period; then single dose of placebo matched to oxycodone (PBO Lac) 30 mg crushed tablet intranasally in fourth intervention period. A washout period of at least 5 days (not exceeding 14 days) was maintained between each intervention period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Naloxone Challenge Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Drug Discrimination Phase: Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Drug Discrimination Phase: Day 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Entrance Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Phase: First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Phase: Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Phase: Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Phase: Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Phase: Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Phase: Washout Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Phase: Fourth Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Included all participants enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Liking: Peak Effect (Emax)</title>
        <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the extreme left with &quot;strong disliking&quot; (score of 0 mm) and on the extreme right with &quot;strong liking&quot; (score of 100 mm). Peak Effect (Emax) = Maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Liking: Peak Effect (Emax)</title>
          <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the extreme left with &quot;strong disliking&quot; (score of 0 mm) and on the extreme right with &quot;strong liking&quot; (score of 100 mm). Peak Effect (Emax) = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="1.18"/>
                    <measurement group_id="O2" value="60.5" spread="12.05"/>
                    <measurement group_id="O3" value="51.3" spread="3.32"/>
                    <measurement group_id="O4" value="92.8" spread="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares (LS) mean Difference</param_type>
            <param_value>9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-32.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.0</ci_lower_limit>
            <ci_upper_limit>-27.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.5</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8806</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>41.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.8</ci_lower_limit>
            <ci_upper_limit>46.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>41.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.1</ci_lower_limit>
            <ci_upper_limit>46.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hour</title>
        <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the extreme left with &quot;strong disliking&quot; (score of 0 mm) and on the extreme right with &quot;strong liking&quot; (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hour</title>
          <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the extreme left with &quot;strong disliking&quot; (score of 0 mm) and on the extreme right with &quot;strong liking&quot; (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.518" spread="6.7606"/>
                    <measurement group_id="O2" value="105.286" spread="21.3736"/>
                    <measurement group_id="O3" value="100.241" spread="3.3227"/>
                    <measurement group_id="O4" value="159.580" spread="32.1643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2176</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-54.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.1</ci_lower_limit>
            <ci_upper_limit>-44.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3502</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>15.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7624</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>59.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.0</ci_lower_limit>
            <ci_upper_limit>70.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>61.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.6</ci_lower_limit>
            <ci_upper_limit>71.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High: Peak Effect (Emax)</title>
        <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>High: Peak Effect (Emax)</title>
          <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="10.01"/>
                    <measurement group_id="O2" value="26.6" spread="28.44"/>
                    <measurement group_id="O3" value="6.0" spread="21.84"/>
                    <measurement group_id="O4" value="85.8" spread="24.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>24.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.8</ci_lower_limit>
            <ci_upper_limit>35.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-61.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.6</ci_lower_limit>
            <ci_upper_limit>-50.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>18.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.4</ci_lower_limit>
            <ci_upper_limit>29.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2507</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.2</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>79.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.2</ci_lower_limit>
            <ci_upper_limit>90.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>86.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.4</ci_lower_limit>
            <ci_upper_limit>97.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High: Area Under Effect Curve (AUE) From 0-2 Hour</title>
        <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>High: Area Under Effect Curve (AUE) From 0-2 Hour</title>
          <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" spread="3.5082"/>
                    <measurement group_id="O2" value="27.750" spread="39.7213"/>
                    <measurement group_id="O3" value="4.768" spread="20.0468"/>
                    <measurement group_id="O4" value="135.670" spread="43.0513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>26.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.6</ci_lower_limit>
            <ci_upper_limit>43.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-109.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-125.7</ci_lower_limit>
            <ci_upper_limit>-93.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>21.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.1</ci_lower_limit>
            <ci_upper_limit>37.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5117</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.8</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>130.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114.5</ci_lower_limit>
            <ci_upper_limit>147.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with treatment, period, and sequence as fixed effects, and participants nested within the sequence as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was adjusted using Benjamini-Hochberg method.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>136.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>119.8</ci_lower_limit>
            <ci_upper_limit>152.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Take Drug Again: Peak Effect (Emax)</title>
        <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = “definitely would not”, 50 mm = “do not care”, and 100 mm = “definitely would”). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Take Drug Again: Peak Effect (Emax)</title>
          <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = “definitely would not”, 50 mm = “do not care”, and 100 mm = “definitely would”). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" spread="14.91"/>
                    <measurement group_id="O2" value="58.3" spread="31.99"/>
                    <measurement group_id="O3" value="46.6" spread="18.75"/>
                    <measurement group_id="O4" value="87.8" spread="26.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Take Drug Again: Mean Effect (Emean)</title>
        <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = “definitely would not”, 50 mm = “do not care”, and 100 mm = “definitely would”). Emean = Average observed score.</description>
        <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Take Drug Again: Mean Effect (Emean)</title>
          <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = “definitely would not”, 50 mm = “do not care”, and 100 mm = “definitely would”). Emean = Average observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.71" spread="14.286"/>
                    <measurement group_id="O2" value="52.16" spread="30.926"/>
                    <measurement group_id="O3" value="43.95" spread="17.753"/>
                    <measurement group_id="O4" value="85.34" spread="26.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Take Drug Again Effect at Hours 12 and 24</title>
        <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = “definitely would not”, 50 mm = “do not care”, and 100 mm = “definitely would”).</description>
        <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Take Drug Again Effect at Hours 12 and 24</title>
          <description>Take drug again VAS is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100 mm VAS with score ranging from 0 mm to 100 mm (score of 0 mm = “definitely would not”, 50 mm = “do not care”, and 100 mm = “definitely would”).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" spread="17.36"/>
                    <measurement group_id="O2" value="51.5" spread="32.74"/>
                    <measurement group_id="O3" value="43.2" spread="18.02"/>
                    <measurement group_id="O4" value="87.4" spread="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="17.40"/>
                    <measurement group_id="O2" value="52.8" spread="32.62"/>
                    <measurement group_id="O3" value="44.7" spread="20.66"/>
                    <measurement group_id="O4" value="83.3" spread="28.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Drug Liking: Peak Effect (Emax)</title>
        <description>Overall drug liking VAS assesses the participant’s global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = “strong disliking”, 50 mm = “neither like nor dislike”, and 100 mm= “strong liking”). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Drug Liking: Peak Effect (Emax)</title>
          <description>Overall drug liking VAS assesses the participant’s global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = “strong disliking”, 50 mm = “neither like nor dislike”, and 100 mm= “strong liking”). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="0.84"/>
                    <measurement group_id="O2" value="59.9" spread="21.70"/>
                    <measurement group_id="O3" value="51.5" spread="6.59"/>
                    <measurement group_id="O4" value="85.1" spread="23.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Drug Liking: Mean Effect (Emean)</title>
        <description>Overall drug liking VAS assesses the participant’s global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = “strong disliking”, 50 mm = “neither like nor dislike”, and 100 mm= “strong liking”). Emean = Average observed score.</description>
        <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Drug Liking: Mean Effect (Emean)</title>
          <description>Overall drug liking VAS assesses the participant’s global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = “strong disliking”, 50 mm = “neither like nor dislike”, and 100 mm= “strong liking”). Emean = Average observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.32" spread="0.641"/>
                    <measurement group_id="O2" value="56.77" spread="20.058"/>
                    <measurement group_id="O3" value="49.16" spread="8.131"/>
                    <measurement group_id="O4" value="81.25" spread="24.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Drug Liking Effect at Hours 12 and 24</title>
        <description>Overall drug liking VAS assesses the participant’s global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = “strong disliking”, 50 mm = “neither like nor dislike”, and 100 mm= “strong liking”).</description>
        <time_frame>Intervention period: 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Drug Liking Effect at Hours 12 and 24</title>
          <description>Overall drug liking VAS assesses the participant’s global perception of drug liking (that is, effects over the whole course of the drug experience including any carry-over effects). A 100 mm VAS is used to assess response based on a score ranging from 0 mm to 100 mm (0 mm = “strong disliking”, 50 mm = “neither like nor dislike”, and 100 mm= “strong liking”).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="0.53"/>
                    <measurement group_id="O2" value="56.0" spread="20.69"/>
                    <measurement group_id="O3" value="50.5" spread="2.28"/>
                    <measurement group_id="O4" value="81.8" spread="25.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="0.87"/>
                    <measurement group_id="O2" value="57.6" spread="21.34"/>
                    <measurement group_id="O3" value="47.8" spread="15.02"/>
                    <measurement group_id="O4" value="80.8" spread="25.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Drug Effects: Peak Effect (Emax)</title>
        <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Drug Effects: Peak Effect (Emax)</title>
          <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.42"/>
                    <measurement group_id="O2" value="35.5" spread="31.81"/>
                    <measurement group_id="O3" value="6.2" spread="17.51"/>
                    <measurement group_id="O4" value="88.6" spread="21.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.295" spread="1.0179"/>
                    <measurement group_id="O2" value="18.647" spread="21.1164"/>
                    <measurement group_id="O3" value="1.692" spread="7.6048"/>
                    <measurement group_id="O4" value="69.692" spread="21.7465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.429" spread="1.5517"/>
                    <measurement group_id="O2" value="38.290" spread="43.2746"/>
                    <measurement group_id="O3" value="3.701" spread="16.0503"/>
                    <measurement group_id="O4" value="138.888" spread="48.0836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.830" spread="2.4083"/>
                    <measurement group_id="O2" value="82.371" spread="117.8336"/>
                    <measurement group_id="O3" value="12.513" spread="54.8407"/>
                    <measurement group_id="O4" value="329.004" spread="197.0154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" spread="2.5917"/>
                    <measurement group_id="O2" value="96.013" spread="138.6860"/>
                    <measurement group_id="O3" value="12.585" spread="54.8265"/>
                    <measurement group_id="O4" value="399.719" spread="311.1514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" lower_limit="0.25" upper_limit="24.02"/>
                    <measurement group_id="O2" value="0.517" lower_limit="0.25" upper_limit="12.02"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.23" upper_limit="8.00"/>
                    <measurement group_id="O4" value="0.267" lower_limit="0.25" upper_limit="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Drug Effects: Peak Effect (Emax)</title>
        <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Good Drug Effects: Peak Effect (Emax)</title>
          <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="13.70"/>
                    <measurement group_id="O2" value="25.6" spread="29.60"/>
                    <measurement group_id="O3" value="8.4" spread="17.98"/>
                    <measurement group_id="O4" value="87.9" spread="21.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.804" spread="3.3233"/>
                    <measurement group_id="O2" value="14.263" spread="20.5630"/>
                    <measurement group_id="O3" value="2.393" spread="9.4972"/>
                    <measurement group_id="O4" value="69.464" spread="21.0703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.902" spread="3.5146"/>
                    <measurement group_id="O2" value="26.603" spread="39.6360"/>
                    <measurement group_id="O3" value="5.161" spread="20.4142"/>
                    <measurement group_id="O4" value="138.679" spread="45.7222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.777" spread="10.0925"/>
                    <measurement group_id="O2" value="58.746" spread="110.6803"/>
                    <measurement group_id="O3" value="14.795" spread="62.5301"/>
                    <measurement group_id="O4" value="307.589" spread="191.3034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.420" spread="28.9445"/>
                    <measurement group_id="O2" value="69.246" spread="136.6847"/>
                    <measurement group_id="O3" value="14.795" spread="62.5301"/>
                    <measurement group_id="O4" value="348.732" spread="274.1036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" lower_limit="0.25" upper_limit="8.02"/>
                    <measurement group_id="O2" value="0.275" lower_limit="0.25" upper_limit="2.52"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.23" upper_limit="3.00"/>
                    <measurement group_id="O4" value="0.400" lower_limit="0.25" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bad Drug Effects: Peak Effect (Emax)</title>
        <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Bad Drug Effects: Peak Effect (Emax)</title>
          <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="5.49"/>
                    <measurement group_id="O2" value="13.0" spread="24.52"/>
                    <measurement group_id="O3" value="5.6" spread="15.92"/>
                    <measurement group_id="O4" value="18.5" spread="26.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="0.1674"/>
                    <measurement group_id="O2" value="3.911" spread="7.8416"/>
                    <measurement group_id="O3" value="0.246" spread="1.2050"/>
                    <measurement group_id="O4" value="4.080" spread="9.9234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" spread="0.4053"/>
                    <measurement group_id="O2" value="6.920" spread="12.0601"/>
                    <measurement group_id="O3" value="0.701" spread="3.6120"/>
                    <measurement group_id="O4" value="10.107" spread="21.5289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.482" spread="1.5766"/>
                    <measurement group_id="O2" value="15.000" spread="31.8735"/>
                    <measurement group_id="O3" value="5.719" spread="20.3316"/>
                    <measurement group_id="O4" value="43.232" spread="87.5335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.696" spread="32.9731"/>
                    <measurement group_id="O2" value="19.214" spread="45.0219"/>
                    <measurement group_id="O3" value="6.004" spread="20.3044"/>
                    <measurement group_id="O4" value="71.375" spread="192.3920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" lower_limit="0.25" upper_limit="24.02"/>
                    <measurement group_id="O2" value="0.267" lower_limit="0.25" upper_limit="2.52"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.23" upper_limit="12.00"/>
                    <measurement group_id="O4" value="0.642" lower_limit="0.25" upper_limit="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feel Sick: Peak Effect (Emax)</title>
        <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention periods: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Feel Sick: Peak Effect (Emax)</title>
          <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="9.23"/>
                    <measurement group_id="O2" value="8.7" spread="20.50"/>
                    <measurement group_id="O3" value="3.9" spread="13.34"/>
                    <measurement group_id="O4" value="4.6" spread="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.1438"/>
                    <measurement group_id="O2" value="1.549" spread="5.3704"/>
                    <measurement group_id="O3" value="0.232" spread="1.2041"/>
                    <measurement group_id="O4" value="0.442" spread="1.5106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.545" spread="2.3162"/>
                    <measurement group_id="O2" value="3.424" spread="8.1912"/>
                    <measurement group_id="O3" value="0.714" spread="3.6100"/>
                    <measurement group_id="O4" value="3.049" spread="8.5600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.170" spread="4.6220"/>
                    <measurement group_id="O2" value="9.371" spread="22.4283"/>
                    <measurement group_id="O3" value="4.804" spread="19.8483"/>
                    <measurement group_id="O4" value="25.103" spread="80.5454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.313" spread="4.6839"/>
                    <measurement group_id="O2" value="10.513" spread="24.8145"/>
                    <measurement group_id="O3" value="4.875" spread="19.8377"/>
                    <measurement group_id="O4" value="42.460" spread="144.3171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feel Sick: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Feel Sick: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Feel Sick VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O2" value="0.267" lower_limit="0.25" upper_limit="6.00"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.23" upper_limit="8.00"/>
                    <measurement group_id="O4" value="0.267" lower_limit="0.25" upper_limit="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea: Peak Effect (Emax)</title>
        <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea: Peak Effect (Emax)</title>
          <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="9.25"/>
                    <measurement group_id="O2" value="9.3" spread="20.99"/>
                    <measurement group_id="O3" value="5.3" spread="15.90"/>
                    <measurement group_id="O4" value="12.3" spread="29.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.1477"/>
                    <measurement group_id="O2" value="2.455" spread="5.9882"/>
                    <measurement group_id="O3" value="0.290" spread="1.2186"/>
                    <measurement group_id="O4" value="2.339" spread="6.0186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.473" spread="2.3127"/>
                    <measurement group_id="O2" value="5.179" spread="11.0690"/>
                    <measurement group_id="O3" value="0.781" spread="3.6209"/>
                    <measurement group_id="O4" value="7.357" spread="15.8889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="4.6313"/>
                    <measurement group_id="O2" value="9.063" spread="17.1052"/>
                    <measurement group_id="O3" value="5.353" spread="19.5238"/>
                    <measurement group_id="O4" value="46.402" spread="114.6615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.071" spread="4.6706"/>
                    <measurement group_id="O2" value="10.848" spread="23.1275"/>
                    <measurement group_id="O3" value="5.638" spread="19.5807"/>
                    <measurement group_id="O4" value="58.759" spread="150.9858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Nausea VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" lower_limit="0.25" upper_limit="4.02"/>
                    <measurement group_id="O2" value="0.267" lower_limit="0.25" upper_limit="6.00"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.23" upper_limit="2.52"/>
                    <measurement group_id="O4" value="0.267" lower_limit="0.25" upper_limit="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleepy: Peak Effect (Emax)</title>
        <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleepy: Peak Effect (Emax)</title>
          <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="21.35"/>
                    <measurement group_id="O2" value="35.0" spread="36.04"/>
                    <measurement group_id="O3" value="11.1" spread="28.41"/>
                    <measurement group_id="O4" value="62.9" spread="36.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.813" spread="2.6613"/>
                    <measurement group_id="O2" value="8.848" spread="13.8043"/>
                    <measurement group_id="O3" value="2.920" spread="6.8778"/>
                    <measurement group_id="O4" value="20.464" spread="21.9449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.580" spread="7.9968"/>
                    <measurement group_id="O2" value="34.571" spread="40.4452"/>
                    <measurement group_id="O3" value="8.089" spread="19.0222"/>
                    <measurement group_id="O4" value="61.750" spread="48.0978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.518" spread="52.5582"/>
                    <measurement group_id="O2" value="125.196" spread="157.0183"/>
                    <measurement group_id="O3" value="34.438" spread="92.1369"/>
                    <measurement group_id="O4" value="304.652" spread="210.8188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.875" spread="60.2903"/>
                    <measurement group_id="O2" value="187.839" spread="217.5872"/>
                    <measurement group_id="O3" value="64.795" spread="172.8842"/>
                    <measurement group_id="O4" value="496.652" spread="424.7570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleepy: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleepy: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Sleepy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" lower_limit="0.25" upper_limit="12.02"/>
                    <measurement group_id="O2" value="1.517" lower_limit="0.25" upper_limit="12.02"/>
                    <measurement group_id="O3" value="0.267" lower_limit="0.25" upper_limit="12.02"/>
                    <measurement group_id="O4" value="2.517" lower_limit="0.25" upper_limit="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dizzy: Peak Effect (Emax)</title>
        <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Dizzy: Peak Effect (Emax)</title>
          <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="13.34"/>
                    <measurement group_id="O2" value="7.4" spread="15.74"/>
                    <measurement group_id="O3" value="4.1" spread="15.02"/>
                    <measurement group_id="O4" value="23.5" spread="36.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.1890"/>
                    <measurement group_id="O2" value="1.161" spread="2.7284"/>
                    <measurement group_id="O3" value="0.795" spread="3.1320"/>
                    <measurement group_id="O4" value="9.192" spread="14.5426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.482" spread="2.3628"/>
                    <measurement group_id="O2" value="5.134" spread="14.4253"/>
                    <measurement group_id="O3" value="1.259" spread="4.6194"/>
                    <measurement group_id="O4" value="17.737" spread="28.2806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.286" spread="10.6279"/>
                    <measurement group_id="O2" value="8.482" spread="20.2822"/>
                    <measurement group_id="O3" value="4.938" spread="22.2685"/>
                    <measurement group_id="O4" value="48.826" spread="93.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.143" spread="28.6404"/>
                    <measurement group_id="O2" value="11.768" spread="29.2486"/>
                    <measurement group_id="O3" value="5.152" spread="22.2481"/>
                    <measurement group_id="O4" value="57.469" spread="119.5335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dizzy: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Dizzy: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Dizzy VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267" lower_limit="0.25" upper_limit="8.02"/>
                    <measurement group_id="O2" value="0.267" lower_limit="0.25" upper_limit="12.02"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.23" upper_limit="24.02"/>
                    <measurement group_id="O4" value="0.267" lower_limit="0.25" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Dose (Drug Powder) Insufflated</title>
        <description>The percentage of dose insufflated, was based on a calculation of the weight of powder remaining (if any) following each dosing during the intervention period.</description>
        <time_frame>Intervention period: 0 Hour post-dose</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Dose (Drug Powder) Insufflated</title>
          <description>The percentage of dose insufflated, was based on a calculation of the weight of powder remaining (if any) following each dosing during the intervention period.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" spread="0.000"/>
                    <measurement group_id="O2" value="99.85" spread="0.840"/>
                    <measurement group_id="O3" value="100.00" spread="0.000"/>
                    <measurement group_id="O4" value="99.37" spread="3.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pupillometry: Peak Effect (Emax)</title>
        <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. Emax = Maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose PD data from each period. Here 'N' (number of participants analyzed) signifies those participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pupillometry: Peak Effect (Emax)</title>
          <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. Emax = Maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose PD data from each period. Here 'N' (number of participants analyzed) signifies those participants evaluable for this measure.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.60"/>
                    <measurement group_id="O2" value="-1.7" spread="0.64"/>
                    <measurement group_id="O3" value="-0.7" spread="0.50"/>
                    <measurement group_id="O4" value="-2.9" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
        <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period. Here 'N' (number of participants analyzed) signifies those participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour, 0-2 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. AUE (0-x) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period. Here 'N' (number of participants analyzed) signifies those participants evaluable for this measure.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.333" spread="0.8204"/>
                    <measurement group_id="O2" value="4.746" spread="0.8291"/>
                    <measurement group_id="O3" value="5.132" spread="0.7712"/>
                    <measurement group_id="O4" value="3.229" spread="0.4547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.538" spread="1.7478"/>
                    <measurement group_id="O2" value="9.114" spread="1.6974"/>
                    <measurement group_id="O3" value="10.162" spread="1.5217"/>
                    <measurement group_id="O4" value="5.868" spread="0.8325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.623" spread="6.9054"/>
                    <measurement group_id="O2" value="34.874" spread="6.6910"/>
                    <measurement group_id="O3" value="41.658" spread="6.0399"/>
                    <measurement group_id="O4" value="23.904" spread="3.3208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.666" spread="18.7096"/>
                    <measurement group_id="O2" value="110.574" spread="19.3751"/>
                    <measurement group_id="O3" value="128.937" spread="16.8685"/>
                    <measurement group_id="O4" value="94.012" spread="12.6818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pupillometry: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period. Here 'N' (number of participants analyzed) signifies those participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pupillometry: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties. Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. The same eye for each participant was used for all measurements during the study. TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period. Here 'N' (number of participants analyzed) signifies those participants evaluable for this measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.017" lower_limit="0.53" upper_limit="24.03"/>
                    <measurement group_id="O2" value="3.017" lower_limit="0.53" upper_limit="12.02"/>
                    <measurement group_id="O3" value="2.025" lower_limit="0.53" upper_limit="24.03"/>
                    <measurement group_id="O4" value="0.800" lower_limit="0.52" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hour</title>
        <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the left with &quot;strong disliking&quot; (score of 0 mm) and on the right with &quot;strong liking&quot; (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hour</title>
          <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the left with &quot;strong disliking&quot; (score of 0 mm) and on the right with &quot;strong liking&quot; (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.143" spread="4.2752"/>
                    <measurement group_id="O2" value="53.455" spread="10.0825"/>
                    <measurement group_id="O3" value="49.884" spread="2.7778"/>
                    <measurement group_id="O4" value="81.250" spread="13.1291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.455" spread="17.5470"/>
                    <measurement group_id="O2" value="414.045" spread="61.6430"/>
                    <measurement group_id="O3" value="401.036" spread="3.4801"/>
                    <measurement group_id="O4" value="540.554" spread="122.5684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1198.955" spread="18.4210"/>
                    <measurement group_id="O2" value="1223.902" spread="72.4917"/>
                    <measurement group_id="O3" value="1202.750" spread="6.0623"/>
                    <measurement group_id="O4" value="1397.911" spread="231.2330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Drug Liking: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the left with &quot;strong disliking&quot; (score of 0 mm) and on the right with &quot;strong liking&quot; (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Liking: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of &quot;neither like nor dislike&quot; (score of 50 mm), on the left with &quot;strong disliking&quot; (score of 0 mm) and on the right with &quot;strong liking&quot; (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.383" lower_limit="0.25" upper_limit="3.02"/>
                    <measurement group_id="O2" value="0.758" lower_limit="0.25" upper_limit="8.00"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.23" upper_limit="6.02"/>
                    <measurement group_id="O4" value="0.383" lower_limit="0.25" upper_limit="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>High: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hours</title>
        <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>High: Area Under Effect Curve (AUE) From 0-1 Hour, 0-8 Hour and 0-24 Hours</title>
          <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours*mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.790" spread="3.3474"/>
                    <measurement group_id="O2" value="14.250" spread="20.4883"/>
                    <measurement group_id="O3" value="2.313" spread="9.3978"/>
                    <measurement group_id="O4" value="68.223" spread="19.7926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.049" spread="3.8560"/>
                    <measurement group_id="O2" value="60.143" spread="113.5249"/>
                    <measurement group_id="O3" value="12.955" spread="51.4525"/>
                    <measurement group_id="O4" value="290.670" spread="174.8869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUE (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.121" spread="4.0488"/>
                    <measurement group_id="O2" value="75.429" spread="136.4319"/>
                    <measurement group_id="O3" value="16.598" spread="70.5151"/>
                    <measurement group_id="O4" value="330.813" spread="257.7739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>High: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>High: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from 'none' (score of 0 mm) to 'extremely' (score of 100 mm). TEmax = Time to maximum observed score.</description>
          <population>Completer analysis set included all randomized participants who completed all 4 periods of treatment phase and who contributed to post-dose Pharmacodynamic (PD) data from each period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" lower_limit="0.25" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.275" lower_limit="0.25" upper_limit="24.00"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.23" upper_limit="3.00"/>
                    <measurement group_id="O4" value="0.517" lower_limit="0.25" upper_limit="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject Rating Scale for Nasal Effects: Peak Effect (Emax)</title>
        <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem “as bad as can be”). Emax = Maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Rating Scale for Nasal Effects: Peak Effect (Emax)</title>
          <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem “as bad as can be”). Emax = Maximum observed score.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.1" spread="0.25"/>
                    <measurement group_id="O3" value="0.0" spread="0.32"/>
                    <measurement group_id="O4" value="0.5" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Need to Blow Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.37"/>
                    <measurement group_id="O2" value="0.1" spread="0.61"/>
                    <measurement group_id="O3" value="0.1" spread="0.51"/>
                    <measurement group_id="O4" value="0.4" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose/ Nasal Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.33"/>
                    <measurement group_id="O2" value="0.1" spread="0.57"/>
                    <measurement group_id="O3" value="0.3" spread="0.98"/>
                    <measurement group_id="O4" value="0.4" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial Pain/ Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.19"/>
                    <measurement group_id="O2" value="0.0" spread="0.26"/>
                    <measurement group_id="O3" value="0.1" spread="0.37"/>
                    <measurement group_id="O4" value="0.3" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.46"/>
                    <measurement group_id="O2" value="0.2" spread="0.77"/>
                    <measurement group_id="O3" value="0.4" spread="1.10"/>
                    <measurement group_id="O4" value="0.4" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-1 Hour and 0-2 Hour</title>
        <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem “as bad as can be”). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
        <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-1 Hour and 0-2 Hour</title>
          <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem “as bad as can be”). AUE (0-x) = Area under the effect versus time curve from time 0 to x hours (0-x).</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>units on a scale*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Burning: AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.025" spread="0.0951"/>
                    <measurement group_id="O3" value="0.033" spread="0.1035"/>
                    <measurement group_id="O4" value="0.184" spread="0.3062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning: AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.025" spread="0.0951"/>
                    <measurement group_id="O3" value="0.033" spread="0.1035"/>
                    <measurement group_id="O4" value="0.270" spread="0.6214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Need to Blow Nose: AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.129" spread="0.3125"/>
                    <measurement group_id="O2" value="0.117" spread="0.3182"/>
                    <measurement group_id="O3" value="0.088" spread="0.2503"/>
                    <measurement group_id="O4" value="0.293" spread="0.4586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Need to Blow Nose: AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="0.4147"/>
                    <measurement group_id="O2" value="0.183" spread="0.5520"/>
                    <measurement group_id="O3" value="0.088" spread="0.2503"/>
                    <measurement group_id="O4" value="0.504" spread="0.8616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose/ Nasal Discharge: AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069" spread="0.2468"/>
                    <measurement group_id="O2" value="0.083" spread="0.3432"/>
                    <measurement group_id="O3" value="0.038" spread="0.1046"/>
                    <measurement group_id="O4" value="0.184" spread="0.3521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose/ Nasal Discharge: AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086" spread="0.3342"/>
                    <measurement group_id="O2" value="0.108" spread="0.4437"/>
                    <measurement group_id="O3" value="0.146" spread="0.4678"/>
                    <measurement group_id="O4" value="0.301" spread="0.6771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial Pain/ Pressure: AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.0464"/>
                    <measurement group_id="O2" value="0.033" spread="0.1428"/>
                    <measurement group_id="O3" value="0.042" spread="0.1367"/>
                    <measurement group_id="O4" value="0.066" spread="0.2057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial Pain/ Pressure: AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.0464"/>
                    <measurement group_id="O2" value="0.050" spread="0.2312"/>
                    <measurement group_id="O3" value="0.050" spread="0.1416"/>
                    <measurement group_id="O4" value="0.184" spread="0.6270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: AUE (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172" spread="0.4111"/>
                    <measurement group_id="O2" value="0.175" spread="0.3664"/>
                    <measurement group_id="O3" value="0.200" spread="0.3934"/>
                    <measurement group_id="O4" value="0.250" spread="0.3269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: AUE (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.259" spread="0.6399"/>
                    <measurement group_id="O2" value="0.250" spread="0.5835"/>
                    <measurement group_id="O3" value="0.242" spread="0.4956"/>
                    <measurement group_id="O4" value="0.484" spread="0.7853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject Rating Scale for Nasal Effects: Time to Maximum (Peak) Effect (TEmax)</title>
        <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem “as bad as can be”). TEmax = Time to maximum observed score.</description>
        <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2 hours post-dose</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Rating Scale for Nasal Effects: Time to Maximum (Peak) Effect (TEmax)</title>
          <description>Participant-rated scale for nasal effects was used to assess burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion using a 6-point scale (where, 0 = not present/no problem; 1 = very mild problem; 2 = mild/slight problem; 3 = moderate problem; 4 = severe problem; 5 = problem “as bad as can be”). TEmax = Time to maximum observed score.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.517" lower_limit="0.50" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.517" lower_limit="0.50" upper_limit="0.60"/>
                    <measurement group_id="O3" value="0.517" lower_limit="0.48" upper_limit="0.55"/>
                    <measurement group_id="O4" value="0.517" lower_limit="0.50" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Need to Blow Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.517" lower_limit="0.50" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.517" lower_limit="0.50" upper_limit="0.60"/>
                    <measurement group_id="O3" value="0.517" lower_limit="0.48" upper_limit="0.55"/>
                    <measurement group_id="O4" value="0.517" lower_limit="0.50" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose/ Nasal Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.517" lower_limit="0.50" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.517" lower_limit="0.50" upper_limit="0.75"/>
                    <measurement group_id="O3" value="0.517" lower_limit="0.48" upper_limit="1.52"/>
                    <measurement group_id="O4" value="0.517" lower_limit="0.50" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial Pain/ Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.517" lower_limit="0.50" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.517" lower_limit="0.50" upper_limit="0.60"/>
                    <measurement group_id="O3" value="0.517" lower_limit="0.48" upper_limit="2.00"/>
                    <measurement group_id="O4" value="0.517" lower_limit="0.50" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.517" lower_limit="0.50" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.517" lower_limit="0.50" upper_limit="0.75"/>
                    <measurement group_id="O3" value="0.517" lower_limit="0.48" upper_limit="0.78"/>
                    <measurement group_id="O4" value="0.525" lower_limit="0.50" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Oxycodone, Oxymorphone and Noroxycodone</title>
        <description>Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the pharmacokinetic (PK) parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Oxycodone, Oxymorphone and Noroxycodone</title>
          <description>Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the pharmacokinetic (PK) parameters of interest.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.93" spread="13.706"/>
                    <measurement group_id="O2" value="82.63" spread="19.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4613" spread="0.25684"/>
                    <measurement group_id="O2" value="0.3441" spread="0.16644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.02" spread="10.858"/>
                    <measurement group_id="O2" value="18.88" spread="6.8506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Naltrexone and 6-beta-naltrexol</title>
        <description>Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Naltrexone and 6-beta-naltrexol</title>
          <description>Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naltrexone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.574" spread="1.4093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-beta-naltrexol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.085" spread="1.2948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxycodone, Oxymorphone and Noroxycodone</title>
        <description>Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxycodone, Oxymorphone and Noroxycodone</title>
          <description>Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies participants evaluable for specified category for each arm, respectively.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone (n = 30, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="0.283" upper_limit="4.07"/>
                    <measurement group_id="O2" value="0.475" lower_limit="0.283" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone (n = 29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="1.05" upper_limit="4.07"/>
                    <measurement group_id="O2" value="2.55" lower_limit="0.550" upper_limit="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone (n = 30, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="1.05" upper_limit="6.08"/>
                    <measurement group_id="O2" value="4.05" lower_limit="2.05" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone and 6-beta-naltrexol</title>
        <description>Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone and 6-beta-naltrexol</title>
          <description>Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naltrexone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.317" lower_limit="0.283" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Beta-naltrexol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="0.767" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Decay Half-Life (t1/2) of Oxycodone, Oxymorphone and Noroxycodone</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2) of Oxycodone, Oxymorphone and Noroxycodone</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies participants evaluable for specified category for each arm, respectively.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone (n = 30, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.171" spread="0.65437"/>
                    <measurement group_id="O2" value="4.134" spread="0.87884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone (n = 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported when fewer than 3 participant were evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data was not reported when fewer than 3 participant were evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone (n = 28, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.116" spread="1.2582"/>
                    <measurement group_id="O2" value="7.101" spread="0.89387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Decay Half-Life (t1/2) of Naltrexone and 6-beta-naltrexol</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies those participants who were evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2) of Naltrexone and 6-beta-naltrexol</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies those participants who were evaluable for specified category.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naltrexone (n = 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.577" spread="0.71124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-beta-naltrexol (n = 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.230" spread="0.62809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Oxycodone, Oxymorphone and Noroxycodone</title>
        <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Oxycodone, Oxymorphone and Noroxycodone</title>
          <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone: AUC (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.59" spread="10.010"/>
                    <measurement group_id="O2" value="59.56" spread="14.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone: AUC (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.26" spread="21.951"/>
                    <measurement group_id="O2" value="116.3" spread="27.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone: AUC (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.9" spread="64.753"/>
                    <measurement group_id="O2" value="328.2" spread="73.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone: AUC (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09544" spread="0.07603"/>
                    <measurement group_id="O2" value="0.1589" spread="0.10643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone: AUC (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4023" spread="0.26464"/>
                    <measurement group_id="O2" value="0.4211" spread="0.25186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone: AUC (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.979" spread="1.1448"/>
                    <measurement group_id="O2" value="1.856" spread="0.99704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone: AUC (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.726" spread="4.0397"/>
                    <measurement group_id="O2" value="6.410" spread="2.8655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone: AUC (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.37" spread="15.014"/>
                    <measurement group_id="O2" value="18.91" spread="7.1716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone: AUC (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.7" spread="46.804"/>
                    <measurement group_id="O2" value="119.9" spread="40.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Oxycodone, Oxymorphone and Noroxycodone</title>
        <description>Area under the plasma concentration time-curve from zero to the last quantifiable concentration (AUClast). Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Oxycodone, Oxymorphone and Noroxycodone</title>
          <description>Area under the plasma concentration time-curve from zero to the last quantifiable concentration (AUClast). Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353.0" spread="103.13"/>
                    <measurement group_id="O2" value="435.3" spread="112.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.498" spread="1.6933"/>
                    <measurement group_id="O2" value="2.469" spread="1.8058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.6" spread="95.277"/>
                    <measurement group_id="O2" value="248.5" spread="84.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Oxycodone, Oxymorphone and Noroxycodone</title>
        <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Oxycodone, Oxymorphone and Noroxycodone</title>
          <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received oxycodone and ALO-02 were reported. Oxymorphone and noroxycodone are metabolites of oxycodone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies participants evaluable for specified category for each arm, respectively.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone (n = 30, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.2" spread="109.33"/>
                    <measurement group_id="O2" value="447.3" spread="123.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxymorphone (n = 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported when fewer than 3 participant were evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data was not reported when fewer than 3 participant were evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noroxycodone (n = 28, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.9" spread="111.42"/>
                    <measurement group_id="O2" value="288.8" spread="104.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Naltrexone and 6-beta-naltrexol</title>
        <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve (AUC) From 0-1 Hour, 0-2 Hour and 0-8 Hour of Naltrexone and 6-beta-naltrexol</title>
          <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naltrexone: AUC (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.127" spread="0.87457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naltrexone: AUC (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.669" spread="1.4721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naltrexone: AUC (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.25" spread="3.0400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-beta-naltrexol: AUC (0-1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.050" spread="0.56296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-beta-naltrexol: AUC (0-2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.862" spread="1.7302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-beta-naltrexol: AUC (0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.78" spread="4.8024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Naltrexone and 6-beta-naltrexol</title>
        <description>Area under the plasma concentration time-curve from zero to the last quantifiable concentration (AUClast). Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Naltrexone and 6-beta-naltrexol</title>
          <description>Area under the plasma concentration time-curve from zero to the last quantifiable concentration (AUClast). Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naltrexone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.07" spread="3.2130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-beta-naltrexol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.28" spread="9.3207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone and 6-beta-naltrexol</title>
        <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
        <time_frame>Intervention period: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies those participants who were evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone and 6-beta-naltrexol</title>
          <description>AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received ALO-02 were reported. 6-Beta-naltrexol is metabolites of naltrexone.</description>
          <population>Parameter analysis set included all enrolled participants who received at least 1 dose of study drug and who had at least 1 of the PK parameters of interest. Here ‘n’ signifies those participants who were evaluable for specified category.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naltrexone (n = 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.71" spread="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-beta-naltrexol (n = 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.85" spread="10.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 3 - 7 days following last study drug administration that were absent before treatment or that worsened relative to pre-treatment state. Symptoms of withdrawal following naloxone administration (naloxone challenge phase) were not collected as adverse events unless they met the criteria for an SAE. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
        <time_frame>Screening up to 3 to 7 days following last study drug administration, or time of early withdrawal</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Naloxone</title>
            <description>Naloxone HCl 0.2 mg intravenously followed by additional 0.6 mg naloxone HCl intravenously, each dose followed by an assessment for signs and symptoms of opioid withdrawal in naloxone challenge phase.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone HCl 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Oxycodone HCl</title>
            <description>Single dose of placebo matched to oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O5">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O7">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 3 - 7 days following last study drug administration that were absent before treatment or that worsened relative to pre-treatment state. Symptoms of withdrawal following naloxone administration (naloxone challenge phase) were not collected as adverse events unless they met the criteria for an SAE. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Clinically Significant Change in Vital Sign Examinations</title>
        <description>Vital signs assessment included measurement of heart rate, systolic and diastolic blood pressures, and respiratory rate. Criteria for clinically significant change in any vital sign examination was based on investigator’s discretion.</description>
        <time_frame>Screening up to 3 to 7 days following last study drug administration, or time of early withdrawal</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Naloxone</title>
            <description>Naloxone HCl 0.2 mg intravenously followed by additional 0.6 mg naloxone HCl intravenously, each dose followed by an assessment for signs and symptoms of opioid withdrawal in naloxone challenge phase.</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone HCl 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Oxycodone HCl</title>
            <description>Single dose of placebo matched to oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O5">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O7">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Vital Sign Examinations</title>
          <description>Vital signs assessment included measurement of heart rate, systolic and diastolic blood pressures, and respiratory rate. Criteria for clinically significant change in any vital sign examination was based on investigator’s discretion.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Clinically Significant Change in End Tidal Carbon Dioxide (EtCO2)</title>
        <description>End-tidal carbon dioxide concentration in the expired air (EtCO2) was monitored using capnography in a sitting position. Criteria for clinically significant change in EtCO2 was based on investigator’s discretion.</description>
        <time_frame>Intervention period: pre-dose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O2">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in End Tidal Carbon Dioxide (EtCO2)</title>
          <description>End-tidal carbon dioxide concentration in the expired air (EtCO2) was monitored using capnography in a sitting position. Criteria for clinically significant change in EtCO2 was based on investigator’s discretion.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Clinically Significant Change in Oxygen Saturation of Hemoglobin (SpO2)</title>
        <description>Oxygen saturation of hemoglobin in blood (SpO2) was monitored using pulse oximetry continuously for 5 hours following dosing in the drug discrimination phase and continuously for 12 hours following dosing in the treatment phase, or longer at the discretion of the investigator. Individual measurement was collected in a sitting position. If SpO2 fall below 90 percent (%), the investigator administered oxygen via nasal cannula at a flow rate sufficient to maintain the SpO2 greater than or equal to 90%. Participants with fall in SpO2 below 90% were reported.</description>
        <time_frame>Drug discrimination phase: pre-dose up to 5 hours; intervention period: pre-dose up to 12 hours</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxycodone HCl 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oxycodone HCl</title>
            <description>Single dose of placebo matched to oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Sugar Spheres</title>
            <description>Single dose of placebo matched to ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O4">
            <title>ALO-02 30 mg</title>
            <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O5">
            <title>Placebo Lactose Tablet</title>
            <description>Single dose of placebo matched to oxycodone 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
          <group group_id="O6">
            <title>Oxycodone 30 mg</title>
            <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Oxygen Saturation of Hemoglobin (SpO2)</title>
          <description>Oxygen saturation of hemoglobin in blood (SpO2) was monitored using pulse oximetry continuously for 5 hours following dosing in the drug discrimination phase and continuously for 12 hours following dosing in the treatment phase, or longer at the discretion of the investigator. Individual measurement was collected in a sitting position. If SpO2 fall below 90 percent (%), the investigator administered oxygen via nasal cannula at a flow rate sufficient to maintain the SpO2 greater than or equal to 90%. Participants with fall in SpO2 below 90% were reported.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Naloxone</title>
          <description>Naloxone HCl 0.2 mg intravenously followed by additional 0.6 mg naloxone HCl intravenously, each dose followed by an assessment for signs and symptoms of opioid withdrawal in naloxone challenge phase.</description>
        </group>
        <group group_id="E2">
          <title>Oxycodone HCl 30 mg</title>
          <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Oxycodone HCl</title>
          <description>Single dose of placebo matched to oxycodone HCl 30 mg crushed tablet intranasally on either of 2 days in drug discrimination phase.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Sugar Spheres</title>
          <description>Single dose of placebo matched to ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
        </group>
        <group group_id="E5">
          <title>ALO-02 30 mg</title>
          <description>Single dose of ALO-02 30 mg/3.6 mg crushed capsule intranasally in any of the first to fourth intervention periods.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Lactose Tablet</title>
          <description>Single dose of placebo matched to oxycodone 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
        </group>
        <group group_id="E7">
          <title>Oxycodone 30 mg</title>
          <description>Single dose of oxycodone HCl 30 mg crushed tablet intranasally in any of the first to fourth intervention periods.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Feeling of relaxation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

